Predictive Oncology (POAI) CEO Awarded 124,959 RSUs; Vesting Date Announced

Rhea-AI Filing Summary

Predictive Oncology Inc. (POAI) reporting person Raymond F. Vennare, who serves as Chief Executive Officer and a director, received a grant of 124,959 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date. Following the grant, the reporting person beneficially owns 132,081 shares of common stock as of the reported transaction. The Form 4 was signed on 09/11/2025 by an attorney-in-fact.

Positive

• Transparent disclosure of an equity grant showing exact RSU count and vesting date
• Grant aligns CEO compensation with continued service through the vesting date

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: CEO received time‑based RSUs that vest in one installment, aligning pay with continued service.

The filing discloses a single grant of 124,959 RSUs to the CEO/director, vesting in full on October 31, 2025, contingent on continued service. This is a standard time‑based equity award used to retain executives and align incentives with shareholder value over the vesting period. The disclosure is routine for executive compensation and provides transparency about potential dilution and future share issuance at vesting.

Securities Analyst

TL;DR: Materiality is limited; this is a compensation disclosure rather than a market-moving transaction.

The Form 4 reports the acquisition of RSUs rather than open‑market purchases or sales. The grant increases the reporting person’s beneficial ownership to 132,081 shares. Because the grant vests on a single future date and carries no purchase price, it represents potential future share issuance but does not affect current cash flow or debt metrics. Investors are informed of executive compensation timing and magnitude.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vennare Raymond F

(Last) (First) (Middle)

C/O PREDICTIVE ONCOLOGY INC.

91 43RD STREET SUITE 110

(Street)

PITTSBURGH PA 15201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Predictive Oncology Inc. [ POAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A		124,959(1)	A	$0.00	132,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on October 31, 2025, subject to continued service through the applicable vesting date.

	/s/ Josh Blacher, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did POAI insider Raymond F. Vennare receive on 09/09/2025?

The reporting person received 124,959 restricted stock units (RSUs) on 09/09/2025.

When do the RSUs granted to POAI's CEO vest?

The RSUs vest in full on October 31, 2025, subject to continued service through that date.

How many shares does the reporting person beneficially own after the reported transaction?

Following the reported transaction the reporting person beneficially owns 132,081 shares of common stock.

Was there any cash paid for the RSUs reported in the Form 4?

No purchase price is reported; the RSUs are shown with a price of $0.00 in the filing.

What roles does the reporting person hold at Predictive Oncology (POAI)?

The filing lists Raymond F. Vennare as both a Director and the Chief Executive Officer of the issuer.